In vivo tumor growth curves (mean ± SEM) in both tumor models demonstrated that treatment of tumor-bearing mice with a-PDL1-TGFβRII was significantly more effective at inhibiting the progression of A375 (p < 0.01, Student’s unpaired t-test) (Fig. 7a) or MDA-MB-231-luc (p < 0.004, Student’s unpaired t-test) (Fig. 7c) tumors compared with the respective a-PD-L1 alone, IgG-TGFβRII alone, and the combination of a-PD-L1 and nonspecific IgG-TGFβRII. The gene discussed is CD274; the disease is neoplasm.